04/09/2026
STUDY FINDS mRNA “VACCINES” COULD INDUCE OR ACCELERATE CANCER VIA 35 DISTINCT MECHANISMS
We conducted the most comprehensive analysis to date examining the link between mRNA “vaccines” and cancer.
The convergent mechanistic, clinical, and population evidence is now clear: TURBO CANCER IS REAL.
We analyzed CDC mortality data and found an estimated 153,000–197,000 EXCESS U.S. CANCER DEATHS since the 2021 mRNA injection rollout.
Here’s a concise breakdown of our findings:
MECHANISTIC EVIDENCE:
35 distinct cancer-promoting mechanisms converge through 4 major routes: (1) protooncogene activation, (2) mutation pressure, (3) protein–protein interaction network interference, and (4) cancer stem-cell clonal acceleration.
Key mechanisms include EGFR/RAS/MAPK and STAT3–MYC activation, p53/BRCA suppression, impaired DNA repair, residual plasmid DNA and SV40 regulatory elements, LINE-1 reverse transcription, m1Ψ-associated frameshifting, chronic LNP inflammation, immune suppression, and cancer stem-cell expansion—pathways capable of promoting genomic instability, uncontrolled growth, immune escape, dormancy reactivation, and metastatic outgrowth.
Our central concurrent-hit model proposes that these processes do not necessarily operate independently or sequentially. Multiple cancer-promoting hits overlap in the same susceptible host, compressing the time required for dormant, indolent, or microscopic disease to become clinically aggressive.
CLINICAL EVIDENCE:
The published clinical literature includes 333 documented turbo cancer cases across 27 countries, involving lymphomas, leukemia, melanoma, breast cancer, lung cancer, glioblastoma and other glial tumors, sarcomas, and pancreatic cancer. The vast majority of these cases occurred following COVID-19 vaccination, with a minority following SARS-CoV-2 infection.
Approximately 86% of the post-vaccination cases occurred after nucleoside-modified mRNA products—about 56% after Pfizer-BioNTech, 25% after Moderna, and another 5% after exposure to both mRNA products across different doses.
Across these cases, recurring patterns include rapid cancer progression, short-latency recurrence, reactivation of previously controlled disease, and tumors involving the injection site or nearby draining lymph nodes.
POPULATION EVIDENCE:
OUR CDC WONDER ANALYSIS: At least 119,130 EXCESS U.S. CANCER DEATHS since 2021, rising to approximately 153,000–197,000 after accounting for mortality displacement
INDEPENDENT CDC WONDER ANALYSIS (): 154,330 excess U.S. cancer deaths since 2021, closely matching our corrected range
UNITED STATES (SEER): Early-onset cancer incidence surged 6.4% in just 2 years, from 2021–2023, alongside sharp increases in brain and nervous-system tumors (+19.5%), colorectal cancer (+19.4%), small-intestine cancer (+15.5%), ovarian cancer (+12.8%), stomach cancer (+7.3%), and female breast cancer (+3.6%).
SOUTH KOREA: A nationwide cohort of 8.4 million people found vaccinated individuals had an increased 1-year cancer risk across 6 cancer types: thyroid, gastric, colorectal, lung, breast, and prostate cancer.
ITALY: Vaccinated residents had a 23% higher risk of cancer hospitalization
mRNA ONCOLOGY DANGER:
The very mRNA platform now linked in our paper to 35 oncogenic mechanisms is being repurposed to TREAT CANCER ITSELF.
The platform can distribute systemically, forcing vulnerable tissues including the HEART and BRAIN to express mutated tumor proteins—raising the risk of off-target immune attack, cardiac injury, and neurological damage.
Even more concerning, the LNP delivery vehicle itself promoted metastatic outgrowth in mice even without mRNA cargo, suggesting that some oncologic liabilities reside in the platform itself—not only the encoded antigen.
The first randomized test of mRNA as monotherapy in residual cancer has now FAILED: a Phase 2 trial of an individualized mRNA neoantigen therapy given to 327 patients with residual colorectal cancer crossed its futility boundary and was TERMINATED on a numerical overall survival imbalance.
OUR CALL:
We call for IMMEDIATE MARKET WITHDRAWAL of nucleoside-modified mRNA-LNP products from broad preventive use and a halt to their expansion into adjuvant and neoadjuvant cancer treatment.
35 mechanisms. Hundreds of documented turbo cancer cases. Up to ~197,000 excess U.S. cancer deaths by our analysis. A failed randomized mRNA cancer trial. And the same technology is now being pushed deeper into oncology.
It’s time to END this madness.
